We are interested in the potential of CGRP and adrenomedullin (ADM) as proinflammatory peptides and have compared the ability of CGRP and ADM to modulate microvascular and nociceptive (thermal hyperalgesic) responses in rat skin. Vasodilator activity was assessed by laser Doppler flowmetry, inflammatory oedema by the extravascular accumulation of i.v.-injected radiolabelled albumin, and neutrophil accumulation by tissue myeloperoxidase. Hyperalgesia was assessed by a thermal hyperalgesimeter in paw skin.
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ADM (30 to 300 pmol) was threefold less potent than CGRP as a vasodilator. CGRP (30 pmol) potentiated oedema formation induced by mediators of increased microvascular permeability, as expected (p < 0.01). However, ADM (30 to 100 pmol) was without a potentiating effect, although ADM (300 pmol) was effective (p < 0.01). By comparison ADM (100 pmol) potentiated cell accumulation induced by the neutrophil attractant IL1-β, whereas CGRP (30 pmol) did not. Thus ADM, like CGRP, has the ability to potentiate inflammatory events in the microcirculation albeit with apparent differential potencies, that are intriguing and possibly related to actions via different receptors. However, despite proinflammatory activity, neither CGRP nor ADM appears to mediate thermal hyperalgesic activity in skin.
The comparative activities of endogenous CGRP and ADM is more difficult to determine but our results so far suggest that ADM mRNA is expressed at microvascular sites in skin as early as 4 h in inflammatory responses, where the increased blood flow can be inhibited by CGRP . The relative contribution of CGRP and ADM is under study.
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